The FDA internal working group convened to explore the potential regulatory pathways for cannabidiol (CBD). After review, the FDA group has concluded that a new regulatory pathway for CBD is needed that balances individuals’ desire for access to CBD products with the regulatory oversight needed to manage risks. The agency is prepared to work with Congress on this matter. The agency denied rulemaking to market CBD products as dietary supplements. The use of CBD raises various safety concerns, especially with long-term use. A new pathway should be developed for CBD products. The FDA claims that the existing foods and dietary supplement authorities provide limited tools for managing the risks associated with CBD products. The group concluded that it is not apparent how CBD products could meet safety standards for dietary supplements or food additives. The working group does not intend to pursue rulemaking allowing CBD in dietary supplements or conventional foods. @ https://www.fda.gov/news-events/press-announcements/fda-concludes-existing-regulatory-frameworks-foods-and-supplements-are-not-appropriate-cannabidiol?utm_medium=email&utm_source=govdelivery
FDA Concludes that existing regulatory frameworks for foods and supplements are not appropriate for cannabidiol
FDA Concludes that Existing Regulatory Frameworks for Foods and Supplements are Not Appropriate for Cannabidiol, Will Work with Congress on a New Way Forward
A new regulatory pathway for CBD is needed that balances individuals’ desire for access to CBD products with the regulatory oversight needed to manage risks.